Related Articles
Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non‑small cell lung carcinoma: A case report and literature review
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS